Janus kinase inhibitor gets PBS listing for eczema

Dermatologists will have another subsidised option for patients battling to control flares with topical therapy

The Janus kinase inhibitor upadacitinib will soon be available on the PBS for severe atopic dermatitis in teenagers and adults who fail to respond to active topical treatments.

From 1 February, an estimated 3600 Australians each year will benefit from the new listing for the oral medication, which is currently only indicated for rheumatoid arthritis, the Federal Government has announced.

Patients must be aged 12 and over, weigh at least 40kg and not be prescribed any other PBS-subsidised biologic for this indication to